|
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors. |
| |
|
Employment - Next Oncology |
Stock and Other Ownership Interests - 1TRIALSP |
Consulting or Advisory Role - Anaveon; Boehringer Ingelheim; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Incyte; Janssen; MAB Discovery; Medscape; Roche; Sanofi; Seagen; Thermo Fisher Scientific |
Speakers' Bureau - MSD; Novartis; Roche; Seagen; Thermo Fisher Scientific |
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst) |
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst) |
| |
|
Consulting or Advisory Role - Fusion Pharmaceuticals; Kanaph Therapeutics |
Speakers' Bureau - AstraZeneca; Eisai |
Research Funding - Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Health (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Biostar (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Celgene (Inst); Centessa Pharmaceuticals (Inst); Coherus Biosciences (Inst); Compugen (Inst); Cullinan Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Georgiamune (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hotspot Therapeutics (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen Research & Development (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo (Inst); LSK BioPharma (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Medikine (Inst); Merck (Inst); Mersana (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Nurix (Inst); Olema Oncology (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyxis (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Tango Therapeutics (Inst); TeneoBio (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst) |
| |
|
Consulting or Advisory Role - Eisai; Exelixis |
| |
|
Honoraria - Blueprint Medicines; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; OncoSec; Regeneron; Roche |
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Exelixis; Merck |
Speakers' Bureau - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Merck |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst) |
| |
|
|
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Sanofi/Aventis (Inst) |
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Evelo Biosciences (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst); Zai Lab (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis |
| |
|
Consulting or Advisory Role - CRC Oncology |
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Hengrui Pharmaceutical (Inst); HiberCell (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Jiangsu Simcere Pharmaceutical Co. Ltd. (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); Novartis (Inst); Nurix (Inst); OncoNano Inc (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Purinomia (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Roche/Blueprint (Inst); Seagen (Inst); Shasqi Inc. (Inst); Shasqi Inc. (Inst); Silverback Therapeutics (Inst); Synlogic (Inst); Taiho Oncology (Inst); Tallac Therapeutics, Inc. (Inst); Tesaro (Inst); Theradex (Inst); Theradex (Inst); Toragen Therapeutics, Inc. (Inst); TransThera Biosciences (Inst); Xencor (Inst); ZielBio (Inst) |
| |
|
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Medarex |
Consulting or Advisory Role - Abbvie; Arcus Biosciences; G1 Therapeutics; Lilly Medical; Mirati Therapeutics |
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxter (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Y-mAbs Therapeutics (Inst) |
| |
|
Consulting or Advisory Role - Penn State Cancer Institute |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicara Therapeutics, Inc (Inst); Ellipses Pharma (Inst); Exelixis (Inst); Fortrea Inc (Inst); Gilead Sciences (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Lilly (Inst); Lisata Therapeutics, Inc. (Inst); Merck Sharp & Dohme (Inst); National Cancer Institute (Inst); Ohio State University (Inst); Syneos Health (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Puma Biotechnology (Inst); Tesaro/GSK (Inst) |
Travel, Accommodations, Expenses - BMS; Pfizer (Inst) |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen |
Speakers' Bureau - Janssen; Roche |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; Immutep |
| |
|
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche |
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche |
Patents, Royalties, Other Intellectual Property - BMS |
| |
|
Consulting or Advisory Role - Bayer (Inst); Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst) |
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst) |
Travel, Accommodations, Expenses - Bayer; Foundation Medicine; Helsinn Therapeutics; Novartis; PharmaMar |
Other Relationship - Clinical Care Options; Medscape |
| |
|
Employment - Ellipses Pharma |
Stock and Other Ownership Interests - Ellipses Pharma |
| |
|
Employment - Ellipses Pharma |
Stock and Other Ownership Interests - Ellipses Pharma |
Consulting or Advisory Role - Ellipses Pharma; Ellipses Pharma |
| |
|
Employment - Ellipses Pharma |
Travel, Accommodations, Expenses - Ellipses Pharma |
| |
|
Employment - Ellipses Pharma; Hospital Corporation of America; SArah CAnnon Research Institute UK; SArah CAnnon Research Institute UK |
Honoraria - BeiGene; Guardant Health; SERVIER |
Consulting or Advisory Role - Engitix; iOnctura |
Research Funding - Sarah Cannon Research Institute |
| |
|
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim (I); Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Gebro Pharma (I); GlaxoSmithKline; IO Biotech; Janssen Biotech (I); Janssen Oncology; Lilly; Merck KGaA; MSD Oncology; Nordic Group (I); Novartis/Pfizer; Pfizer; Roche Pharma AG; Sanofi/Regeneron; Takeda |
Speakers' Bureau - AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim (I); Janssen (I); Janssen Oncology; Medscape; MSD Oncology; Nordic Group (I); Novartis; Pfizer; Roche Pharma AG; Takeda; touchIME |
Travel, Accommodations, Expenses - AstraZeneca Spain; Roche Pharma AG |
Other Relationship - IO Biotech; Janssen Oncology; Novartis |